Company
Every investor coverage indicates participated in a round Amylin raised.
Companies Amylin acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Mark Fineman, Ph.D. | Executive Director of Medical Development and R&D Strategic Relations (former) | Brandon Capital portfolio |
| Mark Fineman | Executive Director of Medical Development and R&D Strategic Relations (former) | Brandon BioCatalyst portfolio |
Stories naming Amylin. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.
Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.